


What is claimed is:

1. A compound comprising Formula I:



I

- 5 wherein:

X is carbon or nitrogen;

Y is carbon;

and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S;

Z is -C(O)- or -S(O)₂-;

R is lower alkyl;

R¹ is hydrogen; lower alkyl;

aryl; arylalkyl; arylaminocarbonyl; wherein the aryl group is optionally substituted with one to two substituents selected from lower alkyl, halo, cyano or lower alkoxy;

heteroaryl or heteroarylalkyl, wherein the aryl group is optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano, or lower alkyl;

R², R³, and R⁴ are each independently in each occurrence

hydrogen; lower alkyl;

cycloalkyl or cycloalkylalkyl, wherein the cycloalkyl group is optionally substituted with one or more substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halo-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro,

5
10
15
20
25
30

hydroxy; hydroxyalkyl; alkoxy; alkoxyalkyl;
halo; haloalkyl; cyano; cyanoalkyl;
-(CH₂)₀₋₃NR'R"; -C(NH)-NR'R"; -N-C(NR')-R"; -N=CR'-NR'R"; -SO₂NR'R";
-NSO₂R'; -C(O)R'; -C(O)NR' R"; or -NC(O)R';

5 with the proviso that if A is a benzene ring, at least one of R², R³ or R⁴ is
not hydrogen; or

R² and R³, if adjacent, taken together with the carbons to which they are attached
may also form a 5- to 7- membered aromatic, saturated or unsaturated ring,
optionally incorporating one or two ring heteroatoms chosen from N, S, or O,
10 which can be optionally substituted with one or two substituents selected
from lower alkyl, halo, cyano, alkylthio, or lower alkoxy; and

R' and R" are independently in each occurrence

hydrogen; lower alkyl; substituted lower alkyl;

hydroxyalkyl; alkoxyalkyl;

15 cycloalkyl, wherein the cycloalkyl group is optionally substituted with one or
more substituents selected from the group consisting of hydroxy, cyano,
lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen,
haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino,
alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl,
20 alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl,
arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and phenyl;

aryl or arylalkyl, wherein the aryl group is optionally substituted with one or
more substituents selected from the group consisting of hydroxy, cyano,
lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen,
25 haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino,
alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl,
alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl,
arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino,
or two adjacent atoms of the aryl ring can be substituted with a
30 methylenedioxy or ethylenedioxy group;

heteroaryl or heteroarylalkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino;

heterocyclyl or heterocyclylalkyl, wherein the heterocyclyl group is optionally substituted with one to more substituents selected from the group consisting of hydroxy, oxo, cyano, cyanoalkyl, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino;

or R' and R" together with the nitrogen they are attached to may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S; wherein this ring is optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano or lower alkoxy;

or individual isomers, racemic or non-racemic mixtures of isomers or pharmaceutically acceptable salts or solvates thereof.

2. The compound of Claim 1, wherein X is carbon.
3. The compound of Claim 1, wherein X is nitrogen.
4. The compound of Claim 1, wherein R¹ is hydrogen.
5. The compound of Claim 4, wherein X is carbon and A is a fused aryl ring.

6. The compound of Claim 5, wherein A is a fused benzene ring.
7. The compound of Claim 4, wherein X is carbon and A is a fused heteroaryl ring.
8. The compound of Claim 7, wherein A is a fused pyrimidine ring.
9. The compound of Claim 7, wherein A is a fused pyrrole ring.
10. The compound of Claim 9, wherein R² and R³ taken together with the carbons to which they are attached form a fused benzene ring, optionally substituted with one or two substituents selected from lower alkyl, halo, haloalkyl, cyano, lower alkyl, alkylthio, or lower alkoxy.
11. The compound of Claim 7, wherein A is a fused pyridine ring.
12. The compound of Claim 7, wherein A is a fused imidazole ring.
13. The compound of Claim 4, wherein X is nitrogen and A is a fused imidazole ring.
14. The compound of Claim 4, wherein R² is -(CH₂)₀₋₃NR'R" or -SO₂NR'R", and wherein R' and R" are independently in each occurrence hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or R' and R" together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.
15. The compound of Claim 6, wherein R² is -(CH₂)₀₋₃NR'R" or -SO₂NR'R", and wherein R' and R" are independently in each occurrence hydrogen, lower

alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or R' and R" together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

5

16. The compound of Claim 15, wherein Z is -C(O)-.

17. The compound of Claim 15, wherein Z is -S(O)₂-.

10 18. The compound of Claim 6, wherein R² is selected from the groups -C(NH)-NR'R", -N-C(NR')-R", and -N=CR'-NR'R", and wherein R' and R" are independently in each occurrence hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or R' and R" together with the nitrogen they are attached may also form a 5- to 7-
15 membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

19. The compound of Claim 18, wherein Z is -C(O)-.

20 20. A compound of Claim 6, wherein R² is aryl or heteroaryl.

21. A compound of Claim 6, wherein R² is alkoxy, cyano, or cyanoalkyl.

25 22. The compound of Claim 8, wherein R² is -(CH₂)₀₋₃NR'R" or -SO₂NR'R", and wherein R' and R" are independently in each occurrence hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or R' and R" together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional
30 ring heteroatom chosen from N, O, or S.

23. The compound of Claim 22, wherein R^2 is $-NR'R''$, and wherein R' and R'' together with the nitrogen they are attached may also form a 5- to 7-membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

5

24. The compound of Claim 22, wherein Z is $-C(O)-$.

25. The compound of Claim 22, wherein Z is $-S(O)_2-$.

10 26. The compound of Claim 13, wherein R^2 is $-(CH_2)_{0-3}NR'R''$ or $-SO_2NR'R''$, and wherein R' and R'' are independently in each occurrence hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or R' and R'' together with the nitrogen they are attached to may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S.

15

27. The compound of Claim 26, wherein Z is $-C(O)-$.

28. The compound of Claim 26, wherein Z is $-S(O)_2-$.

20

29. The compound of Claim 1, wherein the compound is:
6,7-dimethoxy-2-[5-(4-methoxy-phenyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;
6,7-dimethoxy-2-[7-(4-methoxy-phenyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;
25 6,7-dimethoxy-2-(4-morpholin-4-yl-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-3*H*-quinazolin-4-one;
6,7-dimethoxy-2-(5-pyridin-3-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;
30 2-(4-benzylamino-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-6,7-dimethoxy-3*H*-quinazolin-4-one;

- 6,7-dimethoxy-2-(5-pyrrolidin-1-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;
- 6,7-dimethoxy-2-(5-pyridin-4-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;
- 5 6,7-dimethoxy-2-(5-pyrimidin-5-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;
- 2-(6,7-dimethoxy-4-oxo-1,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid (2-pyridin-2-yl-ethyl)-amide;
- 2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-5-carbonitrile;
- 10 6,7-dimethoxy-2-[5-(1*H*-pyrrol-2-yl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;
- 2-[5-(1*H*-imidazol-2-yl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one;
- 15 6,7-dimethoxy-2-[4-(4-methyl-piperazin-1-yl)-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-3*H*-quinazolin-4-one;
- 6,7-dimethoxy-2-{4-[(2-methoxy-ethyl)-methyl-amino]-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl}-3*H*-quinazolin-4-one;
- 6,7-dimethoxy-2-[5-(morpholine-4-sulfonyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;
- 20 6,7-dimethoxy-2-(4-piperidin-1-yl-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-3*H*-quinazolin-4-one;
- 6,7-dimethoxy-2-[5-(1-morpholin-4-yl-methanoyl)-3,4-dihydro-3*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;
- 25 6,7-dimethoxy-2-(1-phenyl-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl)-3*H*-quinazolin-4-one;
- 2-[1-(4-chloro-phenyl)-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one;
- 6,7-dimethoxy-2-(1-naphthalen-2-yl-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl)-3*H*-quinazolin-4-one;
- 30

6,7-dimethoxy-2-[1-(4-methoxy-phenyl)-1,4,6,7-tetrahydro-imidazo[4,5-
c]pyridin-5-yl]-3*H*-quinazolin-4-one;

2-[1-(3-chloro-phenyl)-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl]-6,7-
dimethoxy-3*H*-quinazolin-4-one;

5 6,7-dimethoxy-2-(1-*m*-tolyl-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl)-3*H*-
quinazolin-4-one;

6,7-dimethoxy-2-(3-phenyl-5,6-dihydro-8*H*-imidazo[1,5-*a*]pyrazin-7-yl)-1*H*-
quinazolin-4-one;

10 2-(3-cyclohexyl-5,6-dihydro-8*H*-imidazo[1,5-*a*]pyrazin-7-yl)-6,7-dimethoxy-1*H*-
quinazolin-4-one;

6,7-dimethoxy-2-(1,3,4,9-tetrahydro-β-carbolin-2-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(6-methoxy-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3*H*-
quinazolin-4-one;

15 6,7-dimethoxy-2-(7-methylsulfanyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3*H*-
quinazolin-4-one;

2-(3,4-dihydro-1*H*-2,7,10-triaza-anthracen-2-yl)-6,7-dimethoxy-3*H*-quinazolin-
4-one;

3-(6,7-dimethoxy-3,4-dihydro-1*H*-isoquinolin-2-yl)-6,7-dimethoxy-2*H*-
benzo[1,2,4]thiadiazine-1,1-dioxide;

20 2-(cyclohexylamino-5,6-dihydro-8*H*-imidazo[1,5-*a*]pyrazin-7-yl)-6,7-
dimethoxy-2*H*-benzo[1,2,4]thiadiazine-1,1-dioxide;

6,7-dimethoxy-3-(4-morpholin-4-yl-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-
2*H*-benzo[1,2,4]thiadiazine-1,1-dioxide;

25 *N*-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-
isoquinolin-5-yl]-cyclopentanecarboxamidine;

6,7-dimethoxy-2-(5-morpholin-4-ylmethyl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-
quinazolin-4-one;

6,7-dimethoxy-2-(5-piperidin-1-ylmethyl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-
quinazolin-4-one;

30 2-[5-(4,5-dihydro-1*H*-imidazol-2-ylamino)-3,4-dihydro-1*H*-isoquinolin-2-yl]-6,7-
dimethoxy-3*H*-quinazolin-4-one;

N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-cyclobutanecarboxamidine;

N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-butyramidine;

N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-*N,N*-dimethyl-formamidine;

6,7-dimethoxy-2-[5-(1-methyl-4,5-dihydro-3*H*-pyrrol-2-ylamino)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one; or

2-[5-(4,5-dihydro-3*H*-pyrrol-2-ylamino)-3,4-dihydro-1*H*-isoquinolin-2-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one.

30. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Claim 1 in admixture with at least one pharmaceutically acceptable carrier.

31. The pharmaceutical composition of Claim 30 wherein the at least one compound is suitable for administration to a subject having a disease state which is alleviated by treatment with an alpha-1A/B adrenoceptor antagonist.

32. A method of treating a subject which comprises administering to the subject a therapeutically effective amount of one or more compounds of any of Claim 1.

33. The method of Claim 32 wherein the subject has a disease state that is alleviated by treatment with an alpha-1A/B adrenoceptor antagonist.

34. The method of Claim 33 wherein the disease state comprises disorders and symptoms of the urinary tract.


35. The method of Claim 33 wherein the disease state comprises improvement of sexual dysfunction.

36. The method of Claim 33 wherein the disease state comprises benign prostatic hypertrophy and the irritative symptoms associated with it.


37. The method of Claim 33 wherein the disease state comprises pain.

38. The method of Claim 37 wherein the disease state comprises inflammatory pain, neuropathic pain, cancer pain, acute pain, chronic pain, or complex regional pain syndromes.


39. A process for preparing a compound as claimed in Claim 1 which process comprises reacting a compound having a Formula II



wherein L is a leaving group, and R and Z are as defined in Claim 1, with a compound of Formula III:



wherein R^1 , R^2 , R^3 , R^4 , X, and Y are as defined in Claim 1, optionally in the presence of a base as described in the specification, to provide a compound of Formula I :



wherein R, R^1 , R^2 , R^3 , R^4 , X, Y, Z, and A are as defined in Claim 1.